Skip to main content
Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.475
+0.055 (3.87%)
At close: Apr 28, 2026, 4:00 PM EDT
1.480
+0.005 (0.34%)
After-hours: Apr 28, 2026, 4:00 PM EDT

Autolus Therapeutics Revenue

In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 644.94% growth. Autolus Therapeutics had revenue of $24.29M in the quarter ending December 31, 2025, with 83,655.17% growth.

Revenue (ttm)
$75.39M
Revenue Growth
+644.94%
P/S Ratio
5.21
Revenue / Employee
$99,984
Employees
754
Market Cap
392.56M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202575.39M65.27M644.94%
Dec 31, 202410.12M8.42M496.00%
Dec 31, 20231.70M-4.66M-73.30%
Dec 31, 20226.36M4.03M172.96%
Dec 31, 20212.33M615.00K35.86%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Sep 30, 2018 Pro Pro Pro
Sep 30, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Puma Biotechnology 228.37M
Niagen Bioscience 129.42M
Century Therapeutics 109.16M
Enanta Pharmaceuticals 66.98M
X4 Pharmaceuticals 35.11M
Lineage Cell Therapeutics 14.56M
Opus Genetics 14.20M
YD Bio 510.36K
Revenue Rankings

AUTL News

More News